The U.S. FDA has approved Ozempic tablets as the proprietary name for Novo Nordisk’s oral semaglutide formulation for its oral semaglutide formulation in doses of 1.5 mg, 4 mg, and 9 mg for adults with type 2 diabetes. The medication contains the same semaglutide molecule and remains indicated to improve blood glucose control and reduce cardiovascular risk in high-risk adults with type 2 diabetes.
The company stated that aligning the oral and injectable products under the Ozempic name is intended to reduce patient and clinician confusion and improve recognition that both forms contain the same active ingredient. The tablets demonstrated bioequivalence to previously marketed oral semaglutide doses and are expected to offer comparable safety and efficacy.
Novo Nordisk plans to launch the Ozempic pill in the United States in Q2 2026. During the transition period, patients are advised to continue taking Rybelsus as prescribed until further guidance from healthcare professionals and pharmacies becomes available.
Clinicians note that the rebranding may simplify treatment discussions by helping patients clearly distinguish semaglutide options for diabetes from those used primarily for weight management.
Patient Perspective: What This Change Means in Practice
This is not a new medication for diabetes.
Oral semaglutide has been available for several years as Rybelsus. The active ingredient and how it works remain the same.
The new name may make treatment choices clearer.
Using the Ozempic name for both injections and tablets may help patients more easily compare options such as weekly injection versus daily pill.
Switching may happen gradually.
Patients currently taking Rybelsus should continue their medication unless their healthcare professional recommends a change. Pharmacies and clinicians will guide any transition.
The pill still requires careful timing.
Oral semaglutide must be taken on an empty stomach with a small amount of water, followed by a waiting period before eating or taking other medications. Proper timing affects how well it works.
Daily dosing does not mean short-acting.
Even in pill form, semaglutide stays in the body for an extended period. Decisions about stopping the medication should always be discussed with a healthcare professional.
The move reflects a broader trend toward simplifying GLP-1 treatment messaging as oral and injectable options expand.
Sources
